PriceTargets.com logo

Geron - GERN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.75
  • Forecasted Upside: 102.21%
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.36 As of 12/12/2025 05:00 PM ET
▼ -0.03 (-2.16%)

This chart shows the closing price for GERN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Geron Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GERN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GERN

Analyst Price Target is $2.75
▲ +102.21% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Geron in the last 3 months. The average price target is $2.75, with a high forecast of $4.00 and a low forecast of $1.00. The average price target represents a 102.21% upside from the last price of $1.36.

This chart shows the closing price for GERN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 9 polled investment analysts is to hold stock in Geron. This rating has held steady since August 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 2 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/17/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/15/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/13/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
11/12/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
12/12/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/9/2025UBS GroupReiterated RatingNeutral ➝ Neutral
12/9/2025HC WainwrightReiterated RatingNeutral ➝ Neutral
11/5/2025Needham & Company LLCLower TargetBuy ➝ Buy$5.00 ➝ $4.00
10/31/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/10/2025The Goldman Sachs GroupInitiated CoverageSell$1.00
5/8/2025ScotiabankDowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.50
3/12/2025HC WainwrightReiterated RatingNeutral ➝ Neutral
3/12/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
2/27/2025BarclaysReiterated RatingOverweight ➝ Overweight$9.00 ➝ $4.00
2/27/2025ScotiabankLower TargetSector Outperform ➝ Sector Outperform$6.00 ➝ $4.00
2/27/2025Stifel NicolausLower TargetBuy ➝ Buy$8.00 ➝ $4.00
2/27/2025Needham & Company LLCLower TargetBuy ➝ Buy$7.00 ➝ $5.00
2/27/2025B. RileyDowngradeBuy ➝ Neutral$3.50 ➝ $2.00
2/26/2025HC WainwrightDowngradeBuy ➝ Neutral
2/18/2025B. RileyLower TargetBuy ➝ Buy$5.50 ➝ $3.50
1/13/2025Needham & Company LLCBoost TargetBuy ➝ Buy$6.00 ➝ $7.00
12/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
12/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
11/29/2024BarclaysUpgradeStrong-Buy
11/5/2024HC WainwrightInitiated CoverageBuy ➝ Buy$8.00 ➝ $8.00
10/16/2024ScotiabankInitiated CoverageSector Outperform$6.00
9/9/2024Leerink PartnrsUpgradeStrong-Buy
9/9/2024Leerink PartnersInitiated CoverageOutperform$7.00
8/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
8/8/2024WedbushReiterated RatingOutperform$8.00
7/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
6/10/2024BarclaysInitiated CoverageOverweight$9.00
6/10/2024Stifel NicolausBoost TargetBuy ➝ Buy$6.00 ➝ $7.00
6/7/2024Needham & Company LLCBoost TargetBuy ➝ Buy$5.00 ➝ $6.00
6/7/2024WedbushReiterated RatingOutperform ➝ Outperform$7.00 ➝ $7.00
5/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00
4/30/2024Robert W. BairdDowngradeOutperform ➝ Neutral$4.50
4/29/2024TD CowenInitiated CoverageBuy$10.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00
4/10/2024WedbushReiterated RatingOutperform ➝ Outperform$6.00
3/15/2024WedbushReiterated RatingOutperform ➝ Outperform$6.00
3/15/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$4.00 ➝ $5.00
3/15/2024Needham & Company LLCBoost TargetBuy ➝ Buy$4.00 ➝ $5.00
2/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$4.00
9/12/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$4.00
8/29/2023WedbushReiterated RatingOutperform ➝ Outperform$6.00
8/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$4.00
4/21/2023Needham & Company LLCReiterated RatingBuy$4.00
3/27/2023The Goldman Sachs GroupInitiated CoverageNeutral$3.00
3/17/2023WedbushReiterated RatingOutperform$6.00
3/17/2023Needham & Company LLCReiterated RatingBuy$4.00
1/9/2023Needham & Company LLCBoost TargetBuy$3.00 ➝ $4.00
1/9/2023B. RileyBoost Target$4.00 ➝ $5.00
1/4/2023WedbushBoost TargetOutperform$5.00 ➝ $6.00
10/27/2022WedbushInitiated CoverageOutperform$5.00
8/12/2022Needham & Company LLCBoost TargetBuy$2.00 ➝ $3.00
7/28/2022B. RileyReiterated RatingBuy$4.00
7/11/2022HC WainwrightReiterated RatingBuy$7.00
3/11/2022B. RileyReiterated RatingBuy
3/11/2022HC WainwrightReiterated RatingBuy$7.00
11/16/2021HC WainwrightReiterated RatingBuy$7.00
11/1/2021Robert W. BairdInitiated CoverageOutperform$4.00
10/13/2021HC WainwrightReiterated RatingBuy$7.00
7/26/2021Cantor FitzgeraldReiterated RatingOverweight
4/8/2021HC WainwrightReiterated RatingBuy
2/17/2021B. RileyReiterated RatingBuy
(Data available from 12/13/2020 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 43 very positive mentions
  • 87 positive mentions
  • 6 negative mentions
  • 11 very negative mentions
Mentions as of
5/17/2025
  • 10 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/16/2025
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/16/2025
  • 10 very positive mentions
  • 25 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
8/15/2025
  • 28 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/14/2025
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/14/2025
  • 9 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
11/13/2025
  • 9 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/13/2025

Current Sentiment

  • 9 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Geron logo
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $1.36
Low: $1.31
High: $1.39

50 Day Range

MA: $1.22
Low: $1.07
High: $1.39

52 Week Range

Now: $1.36
Low: $1.04
High: $4.00

Volume

10,339,223 shs

Average Volume

6,728,049 shs

Market Capitalization

$868.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Geron?

The following Wall Street research analysts have issued stock ratings on Geron in the last twelve months: B. Riley, Barclays PLC, HC Wainwright, Needham & Company LLC, Scotiabank, Stifel Nicolaus, The Goldman Sachs Group, Inc., UBS Group AG, and Weiss Ratings.
View the latest analyst ratings for GERN.

What is the current price target for Geron?

0 Wall Street analysts have set twelve-month price targets for Geron in the last year. Their average twelve-month price target is $2.75, suggesting a possible upside of 102.2%. Barclays PLC has the highest price target set, predicting GERN will reach $4.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $1.00 for Geron in the next year.
View the latest price targets for GERN.

What is the current consensus analyst rating for Geron?

Geron currently has 2 sell ratings, 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GERN, but not buy more shares or sell existing shares.
View the latest ratings for GERN.

What other companies compete with Geron?

Other companies that are similar to Geron include Alkermes, Amicus Therapeutics, Zenas BioPharma, Celldex Therapeutics and MannKind. Learn More about companies similar to Geron.

How do I contact Geron's investor relations team?

Geron's physical mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company's listed phone number is (650) 473-7700 and its investor relations email address is [email protected]. The official website for Geron is www.geron.com. Learn More about contacing Geron investor relations.